Sophia Genetics SA (SOPH)

Currency in USD
6.690
+0.390(+6.19%)
Closed·
6.369-0.321(-4.80%)
·
SOPH is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
6.0806.690
52 wk Range
2.9607.210
Key Statistics
Prev. Close
6.3
Open
6.25
Day's Range
6.08-6.69
52 wk Range
2.96-7.21
Volume
430.08K
Average Volume (3m)
283.82K
1-Year Change
112.5024%
Book Value / Share
0.99
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
SOPH Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
9.750
Upside
+45.74%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts do not anticipate the company will be profitable this year

Sophia Genetics SA News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Analyst Ratings

5 Buy
0 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 9.750
(+45.74% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
BTIG
Buy9.00+34.53%8.00MaintainAug 05, 2026
H.C. Wainwright
Buy12.00+79.37%-MaintainAug 03, 2026
H.C. Wainwright
Buy12.00+79.37%-New CoverageJul 20, 2026
BTIG
Buy8.00+19.58%-MaintainMay 06, 2026
BTIG
Buy8.00+19.58%7.00MaintainApr 15, 2026

Sophia Genetics SA SWOT Analysis


Data-Driven Growth
SOPHiA GENETICS expands its customer base, adding 20 new clients and achieving 17% year-over-year volume growth, showcasing resilience in a challenging market
Market Headwinds
Explore the impact of conservative biopharma spending and regional softness on SOPHiA's revenue projections, and the company's strategic response
Future Prospects
Delve into SOPHiA's upcoming MSK liquid biopsy offerings and their potential to drive significant revenue growth in fiscal year 2025
Financial Outlook
Analyst price targets range from $5 to $7, with management confident in achieving operating profitability within two years despite current market challenges
Read full SWOT analysis

Sophia Genetics SA Earnings Call Summary for Q2/2026

  • Q2 revenue rose 27% YoY to $23.3M, beating estimates of $21.62M; loss of $0.30/share missed forecast of $0.23/share by 30%
  • Full-year 2026 revenue guidance raised to $94M-$96M from $92M-$94M; expects adjusted EBITDA breakeven by year-end, profitability in H2 2027
  • First companion diagnostic wins with AstraZeneca mark pharma business milestone; U.S. revenue surged 64% with broad-based demand growth
  • Adjusted EBITDA loss narrowed to $8.8M from $12M YoY as operating expenses held flat; gross margin fell to 72.1% from 74.4% on cloud costs
  • Cash position strengthened to $107.7M after $57.5M June offering; CEO says network proven across 1,000+ institutions in 75 countries
Last Updated: 2026-08-04, 09:08 a/m
Read Full Transcript

Earnings

Latest Release
Aug 04, 2026
EPS / Forecast
-0.30 / -0.23
Revenue / Forecast
23.3M / 21.62M
EPS Revisions
Last 90 days

SOPH Income Statement

Compare SOPH to Peers and Sector

Metrics to compare
SOPH
Peers
Sector
Relationship
P/E Ratio
−6.6x−1.7x−0.4x
PEG Ratio
1.210.000.00
Price/Book
6.5x1.0x2.6x
Price / LTM Sales
6.2x1.1x3.0x
Upside (Analyst Target)
41.1%13.8%51.8%
Fair Value Upside
Unlock22.4%7.2%Unlock

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. It offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. The company has a partnership with Synnovis to bring blood-based cancer testing to patients in the United Kingdom and a collaboration with AstraZeneca to develop, validate, and deploy two companion diagnostics (CDx) supporting precision oncology therapies. The company was incorporated in 2011 and is based in Rolle, Switzerland.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
2.98M3.55%18.77M
Other Institutional Investors
49.49M58.99%311.80M
Public Companies & Retail Investors
31.42M37.46%197.97M
Total
83.9M100.00%528.54M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Alychlo NV8.34%6,993,80044,061
Generation Investment Management LLP8.09%6,789,56042,774

People Also Watch

12.41
MNRO
-5.63%
71.97
SPSC
-0.91%
18.20
FLYW
-2.41%
26.96
WRBY
-7.91%

FAQ

What Is the Sophia Genetics (SOPH) Stock Price Today?

The Sophia Genetics stock price today is 6.690 USD.

What Stock Exchange Does Sophia Genetics Trade On?

Sophia Genetics is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Sophia Genetics?

The stock symbol for Sophia Genetics is "SOPH."

What Is the Sophia Genetics Market Cap?

As of today, Sophia Genetics market cap is 536.310M USD.

What Is Sophia Genetics's Earnings Per Share (TTM)?

The Sophia Genetics EPS (TTM) is -1.180.

When Is the Next Sophia Genetics Earnings Date?

Sophia Genetics will release its next earnings report on Nov 10, 2026.

From a Technical Analysis Perspective, Is SOPH a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Sophia Genetics Stock Split?

Sophia Genetics has split 0 times.

How Many Employees Does Sophia Genetics Have?

Sophia Genetics has 415 employees.

What is the current trading status of Sophia Genetics (SOPH)?

As of Aug 06, 2026, Sophia Genetics (SOPH) is trading at a price of 6.690 USD, with a previous close of 6.300 USD. The stock has fluctuated within a day range of 6.080 USD to 6.690 USD, while its 52-week range spans from 2.960 USD to 7.210 USD.

What Is Sophia Genetics (SOPH) Price Target According to Analysts?

The average 12-month price target for Sophia Genetics is 9.750 USD, with a high estimate of 14 USD and a low estimate of 7 USD. 5 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +45.74% Upside potential.

What Is the SOPH Premarket Price?

SOPH's last pre-market stock price is 6.280 USD. The pre-market share volume is 1,540.000, and the stock has decreased by -0.020, or -0.320%.

What Is the SOPH After Hours Price?

SOPH's last after hours stock price is 6.369 USD, the stock has decreased by -0.321, or -4.800%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.